Please login to the form below

Not currently logged in
Email:
Password:

breast cancer drug

This page shows the latest breast cancer drug news and features for those working in and with pharma, biotech and healthcare.

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

Antibody drug conjugate gained approval in US in December. The European Medicines Agency (EMA) has accelerated the assessment of Daiichi Sankyo and AstraZeneca’s HER2-positive breast cancer candidate, fast-tracking ... The drug presents a new challenge

Latest news

  • Immutep slumps on latest efti data in breast cancer Immutep slumps on latest efti data in breast cancer

    down by a third as investors all-but wrote off the drug in breast cancer. ... Immutep certainly isn’t abandoning hope for efti in breast cancer, saying that it is holding on for overall survival data from the study – due in late 2020 – and is still

  • Roche posts minor sales miss in Q4 as biosimilar pressure grows Roche posts minor sales miss in Q4 as biosimilar pressure grows

    Schwan highlighted four of these newer Roche medicines as driving the sales growth, namely  Perjeta (pertuzumab) for HER2-positive breast cancer,   Ocrevus (ocrelizumab) for multiple sclerosis, haemophilia therapy  Hemlibra (emicizumab) and

  • Vyndaqel a bright spot as Pfizer comes under pressure Vyndaqel a bright spot as Pfizer comes under pressure

    The company’s fourth-quarter results saw a 9% drop in revenues to $12.69bn, with breast cancer drug Ibrance (palbociclib) and Xeljanz (tofacitinib) for rheumatoid arthritis both growing but missing ... More than 5, 500 patients had been prescribed the

  • Cosentyx, Entresto drive topline growth for Novartis in Q4 Cosentyx, Entresto drive topline growth for Novartis in Q4

    Following Cosentyx was Entresto, which grew by 71% in Q4 to $1.7bn, an impressive increase from the $430m Novartis posted for the drug in Q3. ... Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer

  • NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

    Ibrance. Pfizer received a positive answer from the cost-effectiveness watchdog, with NICE approving its breast cancer drug Ibrance (palbociclib) for use on the Cancer Drugs Fund. ... people with this type of breast cancer,” said Meindert Boysen,

More from news
Approximately 0 fully matching, plus 213 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    keep it inhibited – and which also run the risk of cancer cells acquiring resistance by developing receptor mutations. ... this way. AstraZeneca’s injectable drug Faslodex (fulvestrant) for breast cancer has been approved since 2002, and acts by

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer therapy Herceptin (trastuzumab) with a cell-killing chemotherapy component designed to improve its ability ... Moreover, they think there

  • Integrating electronic health records into clinical trials Integrating electronic health records into clinical trials

    At the Leveraging EHR for Clinical Research Now! event, leaders from academia, companies including Amgen and AstraZeneca and the US Food and Drug Administration sought to identify the factors that are ... Pfizer, for example, won an expanded FDA label

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    The drug has so far gained approval for use in patients with germline BRCA1/2-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)- negative locally advanced or metastatic breast cancer, ... That’s a measure of its heightened ambitions in

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics